Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of CX-4945 in Combination With Gemcitabine and Cisplatin in the Frontline Treatment of Patients With Cholangiocarcinoma

NCT02128282 is registered in ClinicalTrials.gov with Senhwa Biosciences, Inc. as lead sponsor.

NCT NCT02128282
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02128282 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of CX-4945 in Combination With Gemcitabine and Cisplatin in the Frontline Treatment of Patients With Cholangiocarcinoma
Lead sponsor
Senhwa Biosciences, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2014
Completion date
August 5, 2021
Enrollment
127 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

cholangiocarcinoma